Applied Proteomics, Inc. Appoints Erwin Estigarribia As Vice President, Commercial Operations

SAN DIEGO, May 7, 2015 /PRNewswire/ -- Applied Proteomics Inc., the leading developer of protein-based molecular diagnostics, announced today the appointment of Erwin Estigarribia as Vice President, Commercial Operations. Mr. Estigarribia has more than 15 years of progressive operations experience with companies manufacturing vaccines and diagnostics.

"Applied Proteomics' innovative technology enables the development of novel, non-invasive diagnostics with the potential to uncover and treat diseases earlier than ever before," said Peter Klemm, Ph.D., president and CEO of Applied Proteomics. "Erwin's expertise in the operationalization of diagnostic tests will be integral to the launch of our blood-based colorectal cancer diagnostic test."

"Applied Proteomics has a unique mass spectrometry platform for discovery and subsequent commercialization of blood biomarkers in areas of highest need," said Mr. Estigarribia. "I look forward to building out a commercial infrastructure that will support the company's mission to transform healthcare."

Mr. Estigarribia has extensive experience in the genomics and diagnostics industries. He was most recently with CardioDx as Vice President of Operations responsible for logistics, customer service, reimbursement, CLIA laboratory, and information technology. Prior to joining CardioDx, Mr. Estigarribia was Vice President of Manufacturing and Quality Operations at NuGEN Technologies, and served as Associate Director of Process Development for Novartis Vaccines and Diagnostics (formerly Chiron). He received a B.S. with honors of chemical and bioprocess engineering from Swinburne University of Technology, Melbourne, Australia.

About Applied Proteomics Inc.

Founded in 2007, Applied Proteomics Inc. (API) is advancing the application of proteomics for the development of diagnostics, companion diagnostics, and personalized medicine applications to power better medical decisions and care. API has developed a proprietary, industry-leading proteomics platform solution to make protein-based biomarker discovery possible as a replicable, cost efficient, and highly precise industrial application that is being applied to health diagnostic problems. API's first commercial product is a blood-based screening test for colorectal cancer to help risk stratify patients and drive colonoscopy compliance. In addition to advancing other diagnostic development programs in its pipeline, API remains focused on innovation and disruption within the diagnostics space. API is a privately-held Company headquartered in San Diego, CA.

For more information, please visit http://www.appliedproteomics.com.

Company Contact: Steve Martin, SVP CFO Applied Proteomics, Inc. 858.999.2742, [email protected]

Suggested Articles

After beating the standard of care at keeping testosterone levels down, Myovant's prostate cancer drug fell short in patients with metastatic disease.

A Mount Sinai-led team found that immune cells in the brain protect it from abnormal activation that can lead to behavioral problems.

Results from the small cohort suggest the vaccine triggers comparable immune responses in younger and older adults.